TerminatedNot applicableNCT02177838
Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer
Studying Squamous cell carcinoma of the hypopharynx
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Rutgers, The State University of New Jersey
- Principal Investigator
- Sung KimRutgers Cancer Institute of New Jersey
- Intervention
- cetuximab(biological)
- Enrollment
- 8 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2019
Study locations (1)
- New Jersey Medical School, Newark, New Jersey, United States
Collaborators
National Cancer Institute (NCI) · Rutgers Cancer Institute of New Jersey
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02177838 on ClinicalTrials.govOther trials for Squamous cell carcinoma of the hypopharynx
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07063212A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)Memorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT06761937Thermoradiotherapy for Locally Advanced Head and Neck Cancer PatientsErasmus Medical Center
- RECRUITINGPHASE3NCT06706401Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck CarcinomaCentre Leon Berard
- RECRUITINGNCT06380686Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and OutcomeAIO-Studien-gGmbH
- RECRUITINGPHASE3NCT06525220A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)Merus B.V.
- RECRUITINGPHASE3NCT05333523Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.Radboud University Medical Center
- RECRUITINGPHASE2NCT04858269First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma PatientsWake Forest University Health Sciences
- ACTIVE NOT RECRUITINGPHASE3NCT04590963Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck CancerAstraZeneca
See all trials for Squamous cell carcinoma of the hypopharynx →